TY - JOUR
T1 - Mechanism of immunoreactive atrial natriuretic factor release in an ovine model of endotoxemia
AU - Redl, G.
AU - Woodson, L.
AU - Traber, L. D.
AU - Rogers, C. S.
AU - Abdi, S.
AU - Flynn, J. T.
AU - Herndon, D. N.
AU - Traber, D. L.
PY - 1992
Y1 - 1992
N2 - We have previously reported an increase in plasma levels of atrial natriuretic factor (ANF) in an ovine model of endotoxemia. The purpose of this study was to determine if this IR-ANF release was mediated by the increase of right atrial pressure (RAP) and right heart volumes concomitantly observed following endotoxin (LPS) administration. We studied right ventricular function, renal blood flow (RBF), urinary output (UO), urinary clearance of free water (C(H20)), urinary osmolality (U(OSM)), sodium excretion (UE(NA)), and the plasma IR-ANF concentration (radioimmunoassay), following the administration of an E. coli LPS bolus (1 μg/kg) with (group O, n = 8) and without (group E, n = 10) pretreatment with OKY-046, a selective thromboxane synthetase inhibitor. LPS induced early increases in RAP, right ventricular end-systolic (RVESV) and end-diastolic (RVEDV) volumes, heart rate (HR), and IR-ANF, and delayed increases in RBF, UO, and C(H20). OKY-046 prevented the elevation of RAP, RVEDV, and RVESV; however, both groups showed virtually identical increases in IR-ANF (E:20.03 ± 3.8 to 192.33 ± 35.47 pg/ml, O: 17.9 ± 4.1 to 159.5 ± 23 pg/ml) as well as an increase of HR, RBF, UO, and C(H20). The increase in IR-ANF release noted following the administration of LPS in an ovine model does not appear to be related to the early elevations in right heart volumes or atrial distension.
AB - We have previously reported an increase in plasma levels of atrial natriuretic factor (ANF) in an ovine model of endotoxemia. The purpose of this study was to determine if this IR-ANF release was mediated by the increase of right atrial pressure (RAP) and right heart volumes concomitantly observed following endotoxin (LPS) administration. We studied right ventricular function, renal blood flow (RBF), urinary output (UO), urinary clearance of free water (C(H20)), urinary osmolality (U(OSM)), sodium excretion (UE(NA)), and the plasma IR-ANF concentration (radioimmunoassay), following the administration of an E. coli LPS bolus (1 μg/kg) with (group O, n = 8) and without (group E, n = 10) pretreatment with OKY-046, a selective thromboxane synthetase inhibitor. LPS induced early increases in RAP, right ventricular end-systolic (RVESV) and end-diastolic (RVEDV) volumes, heart rate (HR), and IR-ANF, and delayed increases in RBF, UO, and C(H20). OKY-046 prevented the elevation of RAP, RVEDV, and RVESV; however, both groups showed virtually identical increases in IR-ANF (E:20.03 ± 3.8 to 192.33 ± 35.47 pg/ml, O: 17.9 ± 4.1 to 159.5 ± 23 pg/ml) as well as an increase of HR, RBF, UO, and C(H20). The increase in IR-ANF release noted following the administration of LPS in an ovine model does not appear to be related to the early elevations in right heart volumes or atrial distension.
KW - atrial natriuretic peptide
KW - right heart
KW - sepsis
KW - sheep
KW - thermodilution
UR - http://www.scopus.com/inward/record.url?scp=0026706380&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026706380&partnerID=8YFLogxK
M3 - Article
C2 - 1394862
AN - SCOPUS:0026706380
SN - 0092-6213
VL - 38
SP - 34
EP - 41
JO - Circulatory Shock
JF - Circulatory Shock
IS - 1
ER -